23
Jun

Left far behind in the race to develop cutting-edge drugs for hepatitis C, Boehringer Ingelheim says it is getting out of the field and washing its hands of its lead therapy, faldepravir. …read more

Source: Beaten by rivals, Boehringer surrenders in hep C contest

    

0 No comments